{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:22:22Z","timestamp":1793852542847,"version":"4.6.1"},"reference-count":127,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Anticoagulation is essential for the treatment and prevention of thromboembolic events. Current guidelines recommend direct oral anticoagulants (DOACs) over vitamin K antagonists in DOAC-eligible patients. The major complication of anticoagulation is serious or life-threatening haemorrhage, which may necessitate prompt haemostatic intervention. Reversal of DOACs may also be required for patients in need of urgent invasive procedures. This guideline from the European Society of Anaesthesiology and Intensive Care (ESAIC) aims to provide evidence-based recommendations and suggestions on how to manage patients on DOACs undergoing urgent or emergency procedures including the treatment of DOAC-induced bleeding.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN<\/jats:title>\n            <jats:p>A systematic literature search was performed, examining four drug comparators (dabigatran, rivaroxaban, apixaban, edoxaban) and clinical scenarios ranging from planned to emergency surgery with the outcomes of mortality, haematoma growth and thromboembolic complications. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology was used to assess the methodological quality of the included studies. Consensus on the wording of the recommendations was achieved by a Delphi process.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>So far, no results from prospective randomised trials comparing two active comparators<jats:underline\/> (e.g. a direct reversal agent and an unspecific haemostatic agent such as prothrombin complex concentrate: PCC) have been published yet and the majority of publications were uncontrolled and observational studies. Thus, the certainty of evidence was assessed to be either low or very low (GRADE C). Thirty-five recommendations and clinical practice statements were developed. During the Delphi process, strong consensus (&gt;90% agreement) was achieved in 97.1% of recommendations and consensus (75 to 90% agreement) in 2.9%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DISCUSSION<\/jats:title>\n            <jats:p>DOAC-specific coagulation monitoring may help in patients at risk for elevated DOAC levels, whereas global coagulation tests are not recommended to exclude clinically relevant DOAC levels. In urgent clinical situations, haemostatic treatment using either the direct reversal or nonspecific haemostatic agents should be started without waiting for DOAC level monitoring. DOAC levels above 50\u200ang\u200aml<jats:sup>\u22121<\/jats:sup> may be considered clinically relevant necessitating haemostatic treatment before urgent or emergency procedures. Before cardiac surgery under activated factor Xa (FXa) inhibitors, the use of andexanet alfa is not recommended because of inhibition of unfractionated heparin, which is needed for extracorporeal circulation. In the situation of DOAC overdose without bleeding, no haemostatic intervention is suggested, instead measures to eliminate the DOACs should be taken. Due to the lack of published results from comparative prospective, randomised studies, the superiority of reversal treatment strategy vs. a nonspecific haemostatic treatment is unclear for most urgent and emergency procedures and bleeding. Due to the paucity of clinical data, no recommendations for the use of recombinant activated factor VII as a nonspecific haemostatic agent can be given.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>In the clinical scenarios of DOAC intake before urgent procedures and DOAC-induced bleeding, practitioners should evaluate the risk of bleeding of the procedure and the severity of the DOAC-induced bleeding before initiating treatment. Optimal reversal strategy remains to be determined in future trials for most clinical settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/eja.0000000000001968","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T06:02:22Z","timestamp":1712124142000},"page":"327-350","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":53,"title":["Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding"],"prefix":"10.1097","volume":"41","author":[{"given":"Oliver","family":"Grottke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamer","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Arnaoutoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bolliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fenger-Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"von Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"R1-20251016","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"R2-20251016","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMra1206531","article-title":"Management of antithrombotic therapy in patients undergoing invasive procedures","volume":"368","author":"Baron","year":"2013","journal-title":"N Engl J Med"},{"key":"R3-20251016","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"R4-20251016","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"R5-20251016","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/ALN.0000000000000608","article-title":"Prothrombin complex concentrates in trauma and perioperative bleeding","volume":"122","author":"Grottke","year":"2015","journal-title":"Anesthesiology"},{"key":"R6-20251016","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"R7-20251016","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/15563650.2020.1743846","article-title":"Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis","volume":"58","author":"Athavale","year":"2020","journal-title":"Clin Toxicol (Phila)"},{"key":"R8-20251016","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bja.2018.04.025","article-title":"Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab","volume":"121","author":"Hegemann","year":"2018","journal-title":"Br J Anaesth"},{"key":"R9-20251016","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/jth.13706","article-title":"The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran","volume":"15","author":"Simon","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R10-20251016","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"R11-20251016","doi-asserted-by":"crossref","first-page":"2042098619888133","DOI":"10.1177\/2042098619888133","article-title":"Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation","volume":"10","author":"Carpenter","year":"2019","journal-title":"Ther Adv Drug Saf"},{"issue":"(Suppl 1)","key":"R12-20251016","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/bja\/aet380","article-title":"Perioperative factor concentrate therapy","volume":"111","author":"Tanaka","year":"2013","journal-title":"Br J Anaesth"},{"key":"R13-20251016","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1161\/CIRCULATIONAHA.120.045769","article-title":"Factor Xa inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates","volume":"141","author":"Panos","year":"2020","journal-title":"Circulation"},{"key":"R14-20251016","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"R15-20251016","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/ALN.0000000000002910","article-title":"Four-factor prothrombin complex concentrate for the management of patients receiving direct oral activated factor X inhibitors","volume":"131","author":"Grottke","year":"2019","journal-title":"Anesthesiology"},{"key":"R16-20251016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13054-016-1275-8","article-title":"Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation","volume":"20","author":"Grottke","year":"2016","journal-title":"Crit Care"},{"key":"R17-20251016","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/cc13982","article-title":"Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients","volume":"18","author":"Schochl","year":"2014","journal-title":"Crit Care"},{"key":"R18-20251016","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2516.2009.02164.x","article-title":"Thrombin generation and fibrinolysis in antifactor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa","volume":"16","author":"Bolliger","year":"2010","journal-title":"Haemophilia"},{"issue":"(Suppl 1)","key":"R19-20251016","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0268-960X(03)90000-2","article-title":"A cell-based model of coagulation and the role of factor VIIa","volume":"17","author":"Hoffman","year":"2003","journal-title":"Blood Rev"},{"key":"R20-20251016","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa042991","article-title":"Recombinant activated factor VII for acute intracerebral hemorrhage","volume":"352","author":"Mayer","year":"2005","journal-title":"N Engl J Med"},{"key":"R21-20251016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"key":"R22-20251016","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/EJA.0000000000001803","article-title":"Management of severe peri-operative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care: second update 2022","volume":"40","author":"Kietaibl","year":"2023","journal-title":"Eur J Anaesthesiol"},{"key":"R23-20251016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13054-023-04327-7","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition","volume":"27","author":"Rossaint","year":"2023","journal-title":"Crit Care"},{"key":"R24-20251016","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/anae.14425","article-title":"International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery","volume":"73","author":"Erdoes","year":"2018","journal-title":"Anaesthesia"},{"key":"R25-20251016","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/AAP.0000000000000763","article-title":"Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition)","volume":"43","author":"Horlocker","year":"2018","journal-title":"Reg Anesth Pain Med"},{"key":"R26-20251016","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/EJA.0000000000001600","article-title":"Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC\/ESRA guidelines","volume":"39","author":"Kietaibl","year":"2022","journal-title":"Eur J Anaesthesiol"},{"key":"R27-20251016","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"R28-20251016","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"(Suppl 1)","key":"R29-20251016","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/ijlh.12654","article-title":"Laboratory measurement of the direct oral anticoagulants: indications and impact on management in clinical practice","volume":"39","author":"Wright","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"R30-20251016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2019.08.020","article-title":"DTI\/DXI interferences with global coagulation tests in emergency hospital admissions - results of the prospective Dresden NOAC Registry (NCT01588119)","volume":"182","author":"Wunder","year":"2019","journal-title":"Thromb Res"},{"key":"R31-20251016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/ALN.0000000000001631","article-title":"Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis","volume":"127","author":"Albaladejo","year":"2017","journal-title":"Anesthesiology"},{"key":"R32-20251016","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/bloodadvances.2020002335","article-title":"Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure","volume":"4","author":"Shaw","year":"2020","journal-title":"Blood Adv"},{"key":"R33-20251016","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1055\/s-0038-1639585","article-title":"Risk factors for higher-than-expected residual rivaroxaban plasma concentrations in real-life patients","volume":"118","author":"Kaserer","year":"2018","journal-title":"Thromb Haemost"},{"key":"R34-20251016","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1076029616629759","article-title":"Evaluation of a heparin-calibrated antifactor Xa assay for measuring the anticoagulant effect of oral direct Xa inhibitors","volume":"22","author":"Beyer","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"R35-20251016","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1213\/ANE.0000000000005114","article-title":"Heparin anti-Xa activity, a readily available unique test to quantify apixaban, rivaroxaban, fondaparinux, and danaparoid levels","volume":"132","author":"Boissier","year":"2021","journal-title":"Anesth Analg"},{"key":"R36-20251016","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/ijlh.13159","article-title":"DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register","volume":"42","author":"Cini","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"R37-20251016","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/00365513.2018.1522664","article-title":"Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays","volume":"78","author":"Hillarp","year":"2018","journal-title":"Scand J Clin Lab Invest"},{"key":"R38-20251016","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1161\/STROKEAHA.117.017981","article-title":"Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions","volume":"48","author":"Ebner","year":"2017","journal-title":"Stroke"},{"key":"R39-20251016","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/rth2.12206","article-title":"Fully automated thromboelastograph TEG 6\u200as to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers","volume":"3","author":"Artang","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"R40-20251016","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/jcph.1758","article-title":"Relationship of edoxaban plasma concentration and blood coagulation in healthy volunteers using standard laboratory tests and viscoelastic analysis","volume":"61","author":"Havrdova","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"R41-20251016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/ALN.0000000000003061","article-title":"Correlation of thromboelastography with apparent rivaroxaban concentration: has point-of-care testing improved?","volume":"132","author":"Myers","year":"2020","journal-title":"Anesthesiology"},{"key":"R42-20251016","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/ijlh.12744","article-title":"Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM)","volume":"40","author":"Seyve","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"R43-20251016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2017.03.019","article-title":"Impact of rivaroxaban on point-of-care assays","volume":"153","author":"Fontana","year":"2017","journal-title":"Thromb Res"},{"key":"R44-20251016","first-page":"481","article-title":"In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates","volume":"14","author":"Korber","year":"2016","journal-title":"Blood Transfus"},{"key":"R45-20251016","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/EJA.0000000000000903","article-title":"Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood: A diagnostic test study","volume":"36","author":"Pailleret","year":"2019","journal-title":"Eur J Anaesthesiol"},{"key":"R46-20251016","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/0310057X1604400607","article-title":"The effect of dabigatran on the kaolin-activated whole blood thromboelastogram","volume":"44","author":"Aho","year":"2016","journal-title":"Anaesth Intensive Care"},{"key":"R47-20251016","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/anae.15254","article-title":"A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury","volume":"76","author":"Oberladstatter","year":"2021","journal-title":"Anaesthesia"},{"key":"R48-20251016","doi-asserted-by":"crossref","first-page":"1076029620972473","DOI":"10.1177\/1076029620972473","article-title":"Effect of dabigatran on clotting time in the clotpro ecarin clotting assay: a prospective, single-arm, open-label study","volume":"26","author":"Fong","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"R49-20251016","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1055\/s-0040-1721775","article-title":"Specific point-of-care testing of coagulation in patients treated with dabigatran","volume":"121","author":"Hartig","year":"2021","journal-title":"Thromb Haemost"},{"key":"R50-20251016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13054-017-1619-z","article-title":"Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants","volume":"21","author":"Ebner","year":"2017","journal-title":"Crit Care"},{"key":"R51-20251016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0039-1700545","article-title":"Accuracy of a rapid diagnostic test for the presence of direct oral factor Xa or thrombin inhibitors in urine-a multicenter trial","volume":"120","author":"Harenberg","year":"2020","journal-title":"Thromb Haemost"},{"key":"R52-20251016","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1055\/s-0041-1732437","article-title":"Detection of direct oral anticoagulants in patient urine samples by prototype and commercial test strips for DOACs - a systematic review and meta-analysis","volume":"5","author":"Martini","year":"2021","journal-title":"TH Open"},{"key":"R53-20251016","first-page":"391","article-title":"Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) - September 2016","volume":"37","author":"Albaladejo","year":"2018","journal-title":"Anaesth Crit Care Pain Med"},{"key":"R54-20251016","first-page":"1710","article-title":"Reversal strategies for nonvitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis","volume":"38","author":"Niessner","year":"2017","journal-title":"Eur Heart J"},{"key":"R55-20251016","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"key":"R56-20251016","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost"},{"key":"R57-20251016","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40119-020-00165-8","article-title":"Idarucizumab for emergency reversal of anticoagulant effects of dabigatran: interim results of a Japanese Post-Marketing Surveillance Study","volume":"9","author":"Yasaka","year":"2020","journal-title":"Cardiol Ther"},{"key":"R58-20251016","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1055\/s-0041-1740180","article-title":"Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban","volume":"122","author":"Benz","year":"2022","journal-title":"Thromb Haemost"},{"key":"R59-20251016","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the anticoagulation forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"key":"R60-20251016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12959-017-0129-1","article-title":"The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor","volume":"15","author":"Schultz","year":"2017","journal-title":"Thromb J"},{"key":"R61-20251016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.thromres.2020.06.044","article-title":"Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: hemostatic and thrombotic outcomes","volume":"195","author":"Shaw","year":"2020","journal-title":"Thromb Res"},{"key":"R62-20251016","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000502173","article-title":"Prothrombin complex concentrate before urgent surgery in patients treated with rivaroxaban and apixaban","volume":"143","author":"Barzilai","year":"2020","journal-title":"Acta Haematol"},{"key":"R63-20251016","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/j.wneu.2019.07.234","article-title":"Management of spinal emergencies in patients on direct oral anticoagulants","volume":"131","author":"Beynon","year":"2019","journal-title":"World Neurosurg"},{"key":"R64-20251016","doi-asserted-by":"crossref","first-page":"e017316","DOI":"10.1161\/JAHA.120.017316","article-title":"Predictors of bleeding in the perioperative anticoagulant use for surgery evaluation study","volume":"9","author":"Tafur","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R65-20251016","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"R66-20251016","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.jvca.2020.10.042","article-title":"Successful antithrombin administration in andexanet alfa-associated heparin resistance","volume":"35","author":"Apostel","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R67-20251016","first-page":"390","article-title":"Difficult intraoperative heparinization following andexanet alfa administration","volume":"3","author":"Watson","year":"2019","journal-title":"Clin Pract Cases Emerg Med"},{"key":"R68-20251016","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.athoracsur.2021.03.033","article-title":"STS\/SCA\/AmSECT\/SABM update to the clinical practice guidelines on patient blood management","volume":"112","author":"Tibi","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"R69-20251016","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ejhf.1356","article-title":"Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation","volume":"21","author":"Van Keer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R70-20251016","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1053\/j.jvca.2022.07.016","article-title":"Perioperative management of direct oral anticoagulants in cardiac surgery: practice recommendations based on current evidence","volume":"36","author":"Budd","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R71-20251016","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5761\/atcs.oa.21-00154","article-title":"Hemoadsorption of rivaroxaban and ticagrelor during acute type A aortic dissection operations","volume":"28","author":"Hassan","year":"2022","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"R72-20251016","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.3390\/jcm11195889","article-title":"Removal of apixaban during emergency cardiac surgery using hemoadsorption with a porous polymer bead sorbent","volume":"11","author":"Hassan","year":"2022","journal-title":"J Clin Med"},{"key":"R73-20251016","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2019.07.070","article-title":"Dabigatran reversal with idarucizumab in patients with renal impairment","volume":"74","author":"Eikelboom","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R74-20251016","doi-asserted-by":"crossref","first-page":"599626","DOI":"10.3389\/fmed.2020.599626","article-title":"Dabigatran level before reversal can predict hemostatic effectiveness of idarucizumab in a real-world setting","volume":"7","author":"Gendron","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R75-20251016","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/ijlh.13591","article-title":"Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa","volume":"43","author":"Bourdin","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"R76-20251016","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/bloodadvances.2016003616","article-title":"Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors","volume":"2","author":"Kalathottukaren","year":"2018","journal-title":"Blood Adv"},{"key":"R77-20251016","doi-asserted-by":"crossref","first-page":"e2240145","DOI":"10.1001\/jamanetworkopen.2022.40145","article-title":"Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis","volume":"5","author":"Chaudhary","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R78-20251016","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/STROKEAHA.121.034572","article-title":"Hematoma expansion and clinical outcomes in patients with factor-Xa inhibitor-related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus real-world usual care","volume":"53","author":"Huttner","year":"2022","journal-title":"Stroke"},{"key":"R79-20251016","doi-asserted-by":"crossref","first-page":"e12518","DOI":"10.1002\/rth2.12518","article-title":"A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding","volume":"5","author":"Jaspers","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"R80-20251016","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"R81-20251016","doi-asserted-by":"crossref","first-page":"e1025","DOI":"10.1097\/CCM.0000000000005059","article-title":"Andexanet alfa or prothrombin complex concentrate for factor xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis","volume":"49","author":"Nederpelt","year":"2021","journal-title":"Crit Care Med"},{"key":"R82-20251016","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0885066618800657","article-title":"Evaluation of the use of low-dose 4-factor prothrombin complex concentrate in the reversal of direct oral anticoagulants in bleeding patients","volume":"35","author":"Allison","year":"2020","journal-title":"J Intensive Care Med"},{"key":"R83-20251016","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ajem.2019.12.008","article-title":"Real-world utilization of andexanet alfa","volume":"38","author":"Brown","year":"2020","journal-title":"Am J Emerg Med"},{"key":"R84-20251016","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12028-020-00968-6","article-title":"Efficacy of 4-factor prothrombin complex concentrates in factor Xa inhibitor-associated intracranial bleeding","volume":"34","author":"Korobey","year":"2021","journal-title":"Neurocrit Care"},{"key":"R85-20251016","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamaneurol.2015.3682","article-title":"Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants","volume":"73","author":"Purrucker","year":"2016","journal-title":"JAMA Neurol"},{"key":"R86-20251016","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12028-015-0213-y","article-title":"The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage","volume":"24","author":"Dibu","year":"2016","journal-title":"Neurocrit Care"},{"key":"R87-20251016","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.annemergmed.2017.08.046","article-title":"Assessing bleeding risk in patients with intentional overdoses of novel antiplatelet and anticoagulant medications","volume":"71","author":"Levine","year":"2018","journal-title":"Ann Emerg Med"},{"issue":"(Suppl 1)","key":"R88-20251016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ijlh.13008","article-title":"Oral anticoagulant monitoring: Are we on the right track?","volume":"41","author":"Onundarson","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"R89-20251016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R90-20251016","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R91-20251016","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1160\/TH12-08-0573","article-title":"Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease","volume":"109","author":"Khadzhynov","year":"2013","journal-title":"Thromb Haemost"},{"key":"R92-20251016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40256-013-0055-y","article-title":"Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects","volume":"14","author":"Wang","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"key":"R93-20251016","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/jth.15031","article-title":"Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa","volume":"18","author":"Nederpelt","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R94-20251016","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1161\/STROKEAHA.120.030565","article-title":"Hemostatic efficacy and anti-FXa (factor Xa) reversal with andexanet alfa in intracranial hemorrhage: ANNEXA-4 Substudy","volume":"52","author":"Demchuk","year":"2021","journal-title":"Stroke"},{"key":"R95-20251016","doi-asserted-by":"crossref","first-page":"106070","DOI":"10.1016\/j.clineuro.2020.106070","article-title":"An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage","volume":"195","author":"Giovino","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"R96-20251016","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ajem.2018.05.023","article-title":"Safety and effectiveness of factor eight inhibitor bypassing activity for direct oral anticoagulant-related hemorrhage reversal","volume":"37","author":"Engelbart","year":"2019","journal-title":"Am J Emerg Med"},{"key":"R97-20251016","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1177\/10600280211004583","article-title":"Factor VIII Inhibitor Bypassing Activity (FEIBA) reversal for apixaban and rivaroxaban in patients with acute intracranial and nonintracranial hemorrhage","volume":"55","author":"Hunt","year":"2021","journal-title":"Ann Pharmacother"},{"key":"R98-20251016","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s11239-021-02605-1","article-title":"Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients","volume":"53","author":"Whitaker","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"R99-20251016","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11239-020-02154-z","article-title":"Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products","volume":"51","author":"Castillo","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"R100-20251016","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/bja\/aew259","article-title":"Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay","volume":"117","author":"Schenk","year":"2016","journal-title":"Br J Anaesth"},{"key":"R101-20251016","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/fca-2020-0073","article-title":"Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study","volume":"17","author":"Coleman","year":"2021","journal-title":"Future Cardiol"},{"key":"R102-20251016","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13054-022-04043-8","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis","volume":"26","author":"Costa","year":"2022","journal-title":"Crit Care"},{"key":"R103-20251016","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/2396987319849763","article-title":"European Stroke Organisation Guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage","volume":"4","author":"Christensen","year":"2019","journal-title":"Eur Stroke J"},{"key":"R104-20251016","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019\u200aAHA\/ACC\/HRS Focused Update of the 2014\u200aAHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"R105-20251016","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1007\/s10620-020-06728-y","article-title":"Anticoagulant reversal in gastrointestinal bleeding: review of treatment guidelines","volume":"66","author":"Milling","year":"2021","journal-title":"Dig Dis Sci"},{"key":"R106-20251016","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC Expert Consensus Decision Pathway on Management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R107-20251016","doi-asserted-by":"crossref","first-page":"e12535","DOI":"10.1002\/rth2.12535","article-title":"Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals","volume":"5","author":"Abdulrehman","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"R108-20251016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/imj.13995","article-title":"Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran","volume":"49","author":"Brennan","year":"2019","journal-title":"Intern Med J"},{"key":"R109-20251016","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.thromres.2020.11.010","article-title":"Real-world experience with reversal of dabigatran by idarucizumab","volume":"197","author":"Haastrup","year":"2021","journal-title":"Thromb Res"},{"key":"R110-20251016","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/1747493019895654","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases","volume":"15","author":"Kermer","year":"2020","journal-title":"Int J Stroke"},{"key":"R111-20251016","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCULATIONAHA.118.036710","article-title":"Idarucizumab for dabigatran reversal in the management of patients with gastrointestinal bleeding","volume":"139","author":"Van der Wall","year":"2019","journal-title":"Circulation"},{"key":"R112-20251016","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.3324\/haematol.2013.092767","article-title":"Use of prothrombin complex concentrates for urgent reversal of dabigatran in the emergency department","volume":"98","author":"Diaz","year":"2013","journal-title":"Haematologica"},{"key":"R113-20251016","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2146\/ajhp120055","article-title":"Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma","volume":"69","author":"Dumkow","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"R114-20251016","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.thromres.2014.07.003","article-title":"Thrombotic safety of prothrombin complex concentrate (Beriplex P\/N) for dabigatran reversal in a rabbit model","volume":"134","author":"Herzog","year":"2014","journal-title":"Thromb Res"},{"key":"R115-20251016","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/ALN.0000000000000863","article-title":"Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model","volume":"123","author":"Honickel","year":"2015","journal-title":"Anesthesiology"},{"key":"R116-20251016","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1538-7836.2012.04859.x","article-title":"Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P\/N) in a rabbit model","volume":"10","author":"Pragst","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R117-20251016","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/ALN.0000000000000255","article-title":"Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation","volume":"120","author":"van Ryn","year":"2014","journal-title":"Anesthesiology"},{"key":"R118-20251016","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke"},{"key":"R119-20251016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2017.02.010","article-title":"Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study","volume":"152","author":"Schulman","year":"2017","journal-title":"Thromb Res"},{"key":"R120-20251016","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/CCM.0b013e31827caaa3","article-title":"Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity","volume":"41","author":"Dager","year":"2013","journal-title":"Crit Care Med"},{"key":"R121-20251016","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2018.11.009","article-title":"Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants","volume":"173","author":"Dager","year":"2019","journal-title":"Thromb Res"},{"key":"R122-20251016","doi-asserted-by":"crossref","first-page":"bcr2014209057","DOI":"10.1136\/bcr-2014-209057","article-title":"Emergency reversal of dabigatran for emergency surgery","volume":"2015","author":"Puttick","year":"2015","journal-title":"BMJ Case Rep"},{"key":"R123-20251016","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc13717","article-title":"Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation\/liver trauma experimental model","volume":"18","author":"Grottke","year":"2014","journal-title":"Crit Care"},{"key":"R124-20251016","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00277-014-2039-7","article-title":"The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa","volume":"93","author":"Htun","year":"2014","journal-title":"Ann Hematol"},{"key":"R125-20251016","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2011-11-393587","article-title":"Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding","volume":"119","author":"Warkentin","year":"2012","journal-title":"Blood"},{"key":"R126-20251016","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.05.004","article-title":"Intravenous thrombolysis in patients with acute ischemic stroke after a reversal of dabigatran anticoagulation with idarucizumab: a real-world clinical experience","volume":"27","author":"Sanak","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R127-20251016","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"}],"container-title":["European Journal of Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/EJA.0000000000001968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:00:51Z","timestamp":1760590851000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/EJA.0000000000001968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":127,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/eja.0000000000001968","relation":{},"ISSN":["0265-0215","1365-2346"],"issn-type":[{"value":"0265-0215","type":"print"},{"value":"1365-2346","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}